Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - mivacurium chloride, quantity: 2.14 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; water for injections - mivacron is a highly selective, non-depolarising neuromuscular blocking agent with a fast recovery profile and a short duration of action. mivacron is used as an adjunct to general anaesthesia to relax skeletal muscles and to facilitate tracheal intubation and mechanical ventilation. this formulation contains no antimicrobial preservative and is intended for single patient use.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - azithromycin, quantity: 500 mg (equivalent: azithromycin monohydrate, qty 512.029 mg) - injection, powder for - excipient ingredients: sodium hydroxide; citric acid - community acquired pneumonia caused by susceptible organisms in patients who require initial intravenous therapy. in clinical studies efficacy has been demonstrated against chlamydia pneumoniae, haemophilus influenzae, legionella pneumophilia, moraxella catarrhalis, mycoplasma pneumoniae, staphylococcus aureus and streptococcus pneumoniae.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - azithromycin, quantity: 500 mg - injection, powder for - excipient ingredients: sodium hydroxide; citric acid monohydrate - community acquired pneumonia caused by susceptible organisms in patients who require initial intravenous therapy. in clinical studies efficacy has been demonstrated against chlamydia pneumoniae, haemophilus influenzae, legionella pneumophilia, moraxella catarrhalis, mycoplasma pneumoniae, staphylococcus aureus and streptococcus pneumoniae.

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - ibuprofen, quantity: 100 mg/ml - injection, concentrated - excipient ingredients: arginine; water for injections; hydrochloric acid - caldolor injection is indicated in adults for the management of acute mild to moderate post-operative pain and moderate to severe post-operative pain with adjunctive reduced morphine dosage, where an intravenous route of administration is considered clinically necessary.,caldolor is indicated for the reduction of fever in adults where an intravenous route of administration is considered clinically necessary.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi - amiodarone hydrochloride - solution for injection - 50mg/1ml

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - azithromycin dihydrate, quantity: 524.1 mg (equivalent: azithromycin, qty 500 mg) - injection, powder for - excipient ingredients: citric acid; sodium hydroxide - community acquired pneumonia caused by susceptible organisms in patients who require initial intravenous therapy. in clinical studies efficacy has been demonstrated against chlamydia pneumoniae, haemophilus influenzae, legionella pneumophilia, moraxella catarrhalis, mycoplasma pneumoniae, staphylococcus aureus and streptococcus pneumoniae.

Israel - English - Ministry of Health

sanofi israel ltd - amiodarone hydrochloride - solution for injection - amiodarone hydrochloride 50 mg / 1 ml - amiodarone - amiodarone - treatment should be initiated and normally monitored only under hospital or specialist supervision. amiodacore injection is indicated for corronary insufficiency, arrhythmias resistant to other treatments, wolf parkinson white syndrome.amiodacore intravenous can be used where a rapid response is required or where oral administration is not possible.

Australia - English - Department of Health (Therapeutic Goods Administration)

lundbeck australia pty ltd - flupentixol decanoate, quantity: 20 mg - injection, solution - excipient ingredients: fractionated coconut oil - flupenthixol is indicated for the maintenance treatment of chronic schizophrenia and other related chronic psychoses, in patients intolerant of and/or refractory to other depot preparations. flupenthixol is intended for maintenance therapy and not for short-term use ( less than 3 months).

Australia - English - Department of Health (Therapeutic Goods Administration)

lundbeck australia pty ltd - flupentixol decanoate, quantity: 20 mg - injection, solution - excipient ingredients: fractionated coconut oil - flupenthixol is indicated for the maintenance treatment of chronic schizophrenia and other related chronic psychoses, in patients intolerant of and/or refractory to other depot preparations. flupenthixol is intended for maintenance therapy and not for short-term use (less than 3 months). flupenthixol is indicated for the maintenance treatment of chronic schizophrenia and other related chronic psychoses, in patients intolerant of and/or refractory to other depot preparations. flupenthixol is intended for maintenance therapy and not for short term use (less than 3 months).

Australia - English - Department of Health (Therapeutic Goods Administration)

lundbeck australia pty ltd - flupentixol decanoate, quantity: 100 mg - injection, concentrated - excipient ingredients: fractionated coconut oil - flupenthixol is indicated for the maintenance treatment of chronic schizophrenia and other related chronic psychoses, in patients intolerant of and/or refractory to other depot preparations. flupenthixol is intended for maintenance therapy and not for short term use (less than 3 months).